Last reviewed · How we verify
SATRAPLATIN
SATRAPLATIN is a satraplatin drug. It is currently in discontinued development.
Satraplatin works by inhibiting the enzyme DNA repair, which allows cancer-killing chemotherapy drugs to be more effective.
Satraplatin is a small molecule drug in the satraplatin class, originally developed by and currently owned by a pharmaceutical company. Its target and exact mechanism of action are unknown, but it is believed to work by inhibiting DNA repair mechanisms in cancer cells. Satraplatin has not been approved by the FDA for any indications, and its commercial status, patent status, and availability of generic manufacturers are also unknown. Further research is needed to determine its safety and efficacy in treating various cancers. As a result, key safety considerations and potential side effects are currently unclear.
At a glance
| Generic name | SATRAPLATIN |
|---|---|
| Drug class | satraplatin |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | discontinued |
Mechanism of action
Imagine your body's cells have a repair crew that fixes damaged DNA. Satraplatin blocks this repair crew, making it harder for cancer cells to fix their DNA and survive. This allows chemotherapy drugs to be more effective at killing cancer cells.
Approved indications
Common side effects
Key clinical trials
- A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients (PHASE2,PHASE3)
- Satraplatin and Prednisone to Treat Prostate Cancer (PHASE2)
- Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors (PHASE1)
- Satraplatin and Bevacizumab in Treating Patients With Metastatic Prostate Cancer Previously Treated With Docetaxel (NA)
- Utilizing A Genomic Sig for "BRCAness" to Eval the Efficacy of Satraplatin in Men With Met. Castration Resistant Prostate Ca (PHASE2)
- Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers (PHASE1)
- Satraplatin for Locally Advanced Non-Small Cell Lung Cancer With Simultaneous Radiotherapy (PHASE1,PHASE2)
- Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SATRAPLATIN CI brief — competitive landscape report
- SATRAPLATIN updates RSS · CI watch RSS
Frequently asked questions about SATRAPLATIN
What is SATRAPLATIN?
How does SATRAPLATIN work?
What drug class is SATRAPLATIN in?
What development phase is SATRAPLATIN in?
Related
- Drug class: All satraplatin drugs
- Therapeutic area: All drugs in Oncology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing